Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (NRIX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · NRIX · as of Sep 30, 2025
Ownership Breakdown
174
Institutional Holders
▲ 9 vs Q2
$783.33M
Total Inst. Value
▼ $222.62M vs Q2
86.67M
Shares Outstanding
freeFloat 99.99%
84.78M
13F Shares Held
▼ 3.54M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
NRIX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC pharmaceutical preparations | 8.89M | 10.56% | 10.56% | $82.12B | Nov 13, 2025 | ▼ 1.55M |
BLACKROCK, INC. pharmaceutical preparations | 6.76M | 8.04% | 8.04% | $62.49B | Nov 12, 2025 | ▼ 46.1K |
DEEP TRACK CAPITAL, LP pharmaceutical preparations | 6.06M | 7.20% | 7.20% | $55.97B | Nov 14, 2025 | ▼ 7.9K |
VANGUARD GROUP INC pharmaceutical preparations | 4.49M | 5.33% | 5.33% | $41.48B | Nov 7, 2025 | ▲ 23.3K |
BAKER BROS. ADVISORS LP pharmaceutical preparations | 3.88M | 4.61% | 4.61% | $35.87B | Nov 14, 2025 | — held |
COMMODORE CAPITAL LP pharmaceutical preparations | 3.78M | 4.49% | 4.49% | $34.93B | Nov 14, 2025 | ▼ 168.6K |
REDMILE GROUP, LLC pharmaceutical preparations | 3.68M | 4.37% | 4.37% | $33.99B | Nov 14, 2025 | ▼ 54.5K |
VESTAL POINT CAPITAL, LP pharmaceutical preparations | 3.48M | 4.13% | 4.13% | $32.11B | Nov 14, 2025 | ▲ 1.48M |
POINT72 ASSET MANAGEMENT, L.P. pharmaceutical preparations | 2.87M | 3.41% | 3.41% | $26.53B | Nov 14, 2025 | ▼ 832.1K |
STATE STREET CORP pharmaceutical preparations | 2.86M | 3.40% | 3.40% | $26.45B | Nov 14, 2025 | ▲ 330.2K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
24
Increased
+7.33M shares2
New Positions
first time holders16
Decreased
−9.61M shares0
Sold Out
fully exitedNet shares change (top 50)
2.29M
+7.33M / −9.61M
Net new holders
+10
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
NRIX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
18
Buy transactions
19
Sell transactions
0.95
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Ring Christine Chief Legal Officer | Jun 2, 2026 | Sale | 8,148 | $16.60 | $135.3K | 13.6K | Form 4 ↗ |
Silva Paul M director | May 15, 2026 | Award | 31,250 | $15.86 | $495.6K | 31.3K | Form 4 ↗ |
Saltzman Edward C director | May 15, 2026 | Award | 31,250 | $15.86 | $495.6K | 31.3K | Form 4 ↗ |
Reinsdorf Judith A director | May 15, 2026 | Award | 31,250 | $15.86 | $495.6K | 31.3K | Form 4 ↗ |
Lacey David L. director | May 15, 2026 | Award | 31,250 | $15.86 | $495.6K | 31.3K | Form 4 ↗ |
Kapur Anil director | May 15, 2026 | Award | 31,250 | $15.86 | $495.6K | 31.3K | Form 4 ↗ |
DANSEY ROGER D director | May 15, 2026 | Award | 31,250 | $15.86 | $495.6K | 31.3K | Form 4 ↗ |
Baynes Roy D. director | May 15, 2026 | Award | 31,250 | $15.86 | $495.6K | 31.3K | Form 4 ↗ |
GREGORY JULIA P director | May 15, 2026 | Award | 31,250 | $15.86 | $495.6K | 31.3K | Form 4 ↗ |
van Houte Hans Chief Financial Officer | May 5, 2026 | Sale | 13,473 | $16.58 | $223.3K | 38.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Nurix Therapeutics, Inc. (NRIX) is primarily owned by institutional investors, who hold approximately 97.8% of total shares outstanding. Company insiders own approximately 0.01%, while retail and public investors account for the remaining 2.17%.
The largest institutional shareholder of Nurix Therapeutics, Inc. is FMR LLC, holding approximately 8.89 million shares — equal to 10.56% of outstanding shares — as of September 30, 2025.
A total of 174 institutional investors currently hold NRIX stock, with a combined institutional value of approximately $783,330,709 as of the most recent 13F filing period.
Frequently asked questions
NRIX ownershipNurix Therapeutics, Inc. (NRIX) is primarily owned by institutional investors, who hold approximately 97.8% of shares. The largest shareholder is FMR LLC with a 10.56% stake. Company insiders hold 0.01%. Data sourced from SEC Form 13F as of September 30, 2025.